Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 5
2006 1
2007 2
2008 2
2009 5
2010 4
2011 2
2012 7
2013 6
2014 5
2015 8
2016 11
2017 7
2018 9
2019 12
2020 21
2021 15
2022 14
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
Torres T, Chiricozzi A, Puig L, Lé AM, Marzano AV, Dapavo P, Dauden E, Carrascosa JM, Lazaridou E, Duarte G, Carvalho AVE, Romiti R, Rompoti N, Teixeira L, Abreu M, Ippoliti E, Maronese CA, Llamas-Velasco M, Vilarrasa E, Del Alcázar E, Daponte AI, Papoutsaki M, Carugno A, Bellinato F, Gisondi P. Torres T, et al. Among authors: dauden e. Am J Clin Dermatol. 2024 Mar;25(2):333-342. doi: 10.1007/s40257-024-00845-4. Epub 2024 Jan 24. Am J Clin Dermatol. 2024. PMID: 38265746 Free PMC article.
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.
Daudén E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Riera-Monroig J, Garrido J, Llamas-Velasco M. Daudén E, et al. Int J Dermatol. 2024 Apr;63(4):503-511. doi: 10.1111/ijd.16915. Epub 2024 Jan 2. Int J Dermatol. 2024. PMID: 38168847
Implementing well-being in the management of psoriasis: An expert recommendation.
Sommer R, Mrowietz U, Gaarn Du Jardin K, Kasujee I, Martini E, Daudén E, Fabbrocini G, Zink A, Griffiths CEM, Augustin M. Sommer R, et al. Among authors: dauden e. J Eur Acad Dermatol Venereol. 2024 Feb;38(2):302-310. doi: 10.1111/jdv.19567. Epub 2023 Oct 19. J Eur Acad Dermatol Venereol. 2024. PMID: 37822008 Review.
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Berenguer-Ruiz S, et al. Among authors: dauden e. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2517-2525. doi: 10.1111/jdv.19468. Epub 2023 Sep 1. J Eur Acad Dermatol Venereol. 2023. PMID: 37625815
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: dauden e. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, De-la-Cueva P, Martorell-Calatayud A, Ballescà F, Belinchon I, Carretero G, Rodriguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés Rodríguez O, Feltes R, Riera-Monroig J, Dauden E. Chicharro P, et al. Among authors: dauden e. Dermatol Ther. 2022 Dec;35(12):e15929. doi: 10.1111/dth.15929. Epub 2022 Oct 19. Dermatol Ther. 2022. PMID: 36223184
127 results